dual agonist glp 1 and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Structural analysis of the dual

Studies have linked GLP-1 medications to various eye conditions, some of which may lead to vision loss

The global GLP-1 market is estimated to grow from USD 49.3 billion in the current year to USD 157

Policy and Global Health Policy advances in 2025 laid critical groundwork for the next phase of obesity care

Learn what to expect and how lifestyle habits can help maintain your results....

We also describe the development of incretin-based pharmacotherapy, starting with exendin- 4 and ending with the identification of multi-incretin hormone receptor agonists, which appear to be the next major step in the fight against T2DM and obesity

Discover how GLP-1 medications reduce inflammation in rheumatoid arthritis, lupus, psoriatic arthritis & osteoarthritis